These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22691894)

  • 1. Evaluation of cognitive function in healthy older subjects treated with fesoterodine.
    Kay GG; Maruff P; Scholfield D; Malhotra B; Whelan L; Darekar A; Martire DL
    Postgrad Med; 2012 May; 124(3):7-15. PubMed ID: 22691894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
    Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
    Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder-wet Patients over the Age of 75 Years with Mild Cognitive Impairment.
    Rajabali S; Asaana P; Nazari S; Wagg A
    Eur Urol Focus; 2024 Mar; 10(2):325-331. PubMed ID: 38402104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
    Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
    BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
    Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
    J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
    Shin D; Shin KH; Lee S; Lim KS; Cho JY; Jang IJ; Shin SG; Yu KS
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):722-8. PubMed ID: 22853865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.
    Wesnes KA; Edgar C; Tretter RN; Bolodeoku J
    Expert Opin Drug Saf; 2009 Nov; 8(6):615-26. PubMed ID: 19747069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
    Kay GG; Wesnes KA
    BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
    Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
    J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of cognitive function of the elderly population: effects of darifenacin.
    Lipton RB; Kolodner K; Wesnes K
    J Urol; 2005 Feb; 173(2):493-8. PubMed ID: 15643227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of selective and non-selective muscarinic antagonists on gastrointestinal transit and bowel function in healthy women.
    Bharucha AE; Isowa H; Hiro S; Guan Z
    Neurogastroenterol Motil; 2013 Jan; 25(1):e35-43. PubMed ID: 23171069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
    Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
    BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers.
    Hindmarch I; Trick L; Ridout F
    Psychopharmacology (Berl); 2005 Dec; 183(2):133-43. PubMed ID: 16205916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies.
    Herschorn S; Jones JS; Oelke M; MacDiarmid S; Wang JT; Guan Z
    Urology; 2010 May; 75(5):1149-55. PubMed ID: 19914702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
    Kelleher CJ; Tubaro A; Wang JT; Kopp Z
    BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.